| 21494621 |
Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas
Reiter, A,
Siebert, R,
Melnick, A,
Pott, C,
Damm-Welk, C,
Yang, SN,
Klapper, W,
Harder, L,
Vater, I,
Woessmann, W,
Cerchietti, L
|
PLoS One |
2011 |
| 21948233 |
ALK mutations conferring differential resistance to structurally diverse ALK inhibitors
Lovly, CM,
Grütter, C,
Heynck, S,
Sos, ML,
Thomas, RK,
Peifer, M,
Balke-Want, H,
Heuckmann, JM,
Rauh, D,
Koker, M,
Weiss, J,
Pao, W,
Hölzel, M
|
Clin. Cancer Res. |
2011 |
| 23239810 |
Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors
Ceccon, M,
Mologni, L,
Scapozza, L,
Bisson, W,
Gambacorti-Passerini, C
|
Mol. Cancer Res. |
2013 |
| 22570254 |
Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer
Haack, H,
Ren, JM,
Gu, TL,
Zhu, X,
Innocenti, G,
Crosby, K,
Tan, ZP,
Moritz, A,
Yang, YF,
Ren, H,
Rush, J,
Beausoleil, S,
Comb, MJ,
Zhang, Y,
Zhou, XM
|
Cancer Res |
2012 |
| 17185414 |
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK
Melnick, JS,
Ding, P,
Liu, Y,
Li, N,
Hood, TL,
Wan, Y,
Li, L,
Schultz, PG,
Warmuth, M,
Kim, S,
Steensma, R,
Galkin, AV,
Chopiuk, G,
Gray, NS,
Sun, F,
Jiang, J,
Xia, G
|
Proc. Natl. Acad. Sci. U.S.A. |
2007 |
